Novartis (NVS) Reports Positive Phase III Results on MS Drug

                                                                  

Novartis AG NVS announced positive results from the phase III EXPAND study on its pipeline candidate, BAF312 (siponimod).

The randomized, double-blinded, placebo-controlled study was evaluating the efficacy and safety of once-daily oral BAF312 in patients suffering from secondary progressive multiple sclerosis (SPMS).

Results showed that the study met its primary endpoint of a reduction in the risk of disability progression, compared with placebo.

Data from the study will be presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London next month.

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews